Cargando…
Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372818/ https://www.ncbi.nlm.nih.gov/pubmed/37521865 http://dx.doi.org/10.1016/j.apsb.2023.05.003 |
| _version_ | 1785078436696424448 |
|---|---|
| author | Lai, Fangfang Ji, Ming Huang, Lei Wang, Yunchen Xue, Nina Du, Tingting Dong, Kai Yao, Xiaoqing Jin, Jing Feng, Zhiqiang Chen, Xiaoguang |
| author_facet | Lai, Fangfang Ji, Ming Huang, Lei Wang, Yunchen Xue, Nina Du, Tingting Dong, Kai Yao, Xiaoqing Jin, Jing Feng, Zhiqiang Chen, Xiaoguang |
| author_sort | Lai, Fangfang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10372818 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103728182023-07-28 Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] Lai, Fangfang Ji, Ming Huang, Lei Wang, Yunchen Xue, Nina Du, Tingting Dong, Kai Yao, Xiaoqing Jin, Jing Feng, Zhiqiang Chen, Xiaoguang Acta Pharm Sin B Correction Elsevier 2023-07 2023-05-09 /pmc/articles/PMC10372818/ /pubmed/37521865 http://dx.doi.org/10.1016/j.apsb.2023.05.003 Text en © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Correction Lai, Fangfang Ji, Ming Huang, Lei Wang, Yunchen Xue, Nina Du, Tingting Dong, Kai Yao, Xiaoqing Jin, Jing Feng, Zhiqiang Chen, Xiaoguang Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title | Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title_full | Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title_fullStr | Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title_full_unstemmed | Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title_short | Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858] |
| title_sort | author correction to “ypd-30, a prodrug of ypd-29b, is an oral small-molecule inhibitor targeting pd-l1 for the treatment of human cancer” [acta pharmaceutica sinica b 12 (2022) 2845–2858] |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372818/ https://www.ncbi.nlm.nih.gov/pubmed/37521865 http://dx.doi.org/10.1016/j.apsb.2023.05.003 |
| work_keys_str_mv | AT laifangfang authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT jiming authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT huanglei authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT wangyunchen authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT xuenina authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT dutingting authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT dongkai authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT yaoxiaoqing authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT jinjing authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT fengzhiqiang authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 AT chenxiaoguang authorcorrectiontoypd30aprodrugofypd29bisanoralsmallmoleculeinhibitortargetingpdl1forthetreatmentofhumancanceractapharmaceuticasinicab12202228452858 |